Labcorp amends $700M receivables facility to 2029

Labcorp Holdings Inc. amended its receivables purchase agreement on January 28, 2026, extending the scheduled termination date of its receivables facility to January 26, 2029.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Labcorp Holdings Inc. amended its receivables purchase agreement on January 28, 2026, extending the scheduled termination date of its receivables facility to January 26, 2029. The facility continues to provide funding backed by accounts receivable through Labcorp Receivables LLC.

The amendment adds a committed $125 million accordion feature, allowing Labcorp Receivables to increase the facility limit from $700 million to up to $825 million at its option on or before May 29, 2026, and removes a prior 0.10% SOFR yield adjustment. Labcorp Receivables remains a separate legal entity whose creditors have first claim on its assets, with excess collections potentially remitted to Labcorp.

8-K Event Classification

3 items: 1.01, 2.03, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change did Labcorp (LH) make to its receivables facility?

Labcorp amended its receivables purchase agreement to extend the facility’s scheduled termination date to January 26, 2029. It continues using Labcorp Receivables LLC to finance receivables, helping support ongoing liquidity through a structured funding arrangement backed by customer payment streams.

How large is Labcorp’s amended receivables facility and accordion option?

The receivables facility maintains a $700 million limit, with a new committed $125 million accordion feature. This accordion allows Labcorp Receivables to increase the facility limit to up to $825 million at its option on or before May 29, 2026, subject to agreement terms.

What pricing change did Labcorp make in the receivables purchase amendment?

The amendment removed a 0.10% SOFR adjustment that previously applied to capital accruing yield at daily one-month SOFR or term SOFR rates. Eliminating this add-on modestly lowers the referenced yield component within the facility’s pricing structure, based on the stated benchmark rates.

What is Labcorp Receivables LLC’s relationship to Labcorp Holdings Inc.?

Labcorp Receivables LLC is a separate legal entity with its own creditors who have priority over its assets. Its assets are not available to pay Labcorp’s other creditors, although receivables collections exceeding required payments may be remitted back to Labcorp under the agreement.

Who are the key counterparties in Labcorp’s amended receivables agreement?

The parties include Labcorp Receivables LLC, Laboratory Corporation of America Holdings, and PNC Bank, National Association as administrative agent, along with other participating parties. The amendment is acknowledged and agreed by Labcorp Holdings Inc., which maintains its involvement in the receivables funding structure.

Where can investors see the full terms of Labcorp’s receivables amendment?

The full Second Amendment to the Receivables Purchase Agreement is filed as Exhibit 10.1. Labcorp states that its brief description is qualified in its entirety by reference to this exhibit, which contains the complete legal and financial terms governing the amended facility.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/29/2026 - 04:15 PM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

January 28, 2026

(Date of earliest event reported)

LABCORP HOLDINGS INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

1-11353

99-2588107

(State or other jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

358 South Main Street

Burlington

North Carolina

27215

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number including area code) 336-229-1127

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class

Trading Symbol

Name of exchange on which registered

Common Stock, $0.10 par value

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 1.01			Entry into a Material Definitive Agreement.

On January 28, 2026, Labcorp Holdings Inc. (the “Company”) amended its receivables purchase agreement (as amended, the “Receivables Purchase Agreement”) by entering into the Second Amendment to the Receivables Purchase Agreement (the “RPA Amendment”), among Labcorp Receivables LLC (“Labcorp Receivables”), Laboratory Corporation of America Holdings, PNC Bank, National Association, as administrative agent and the other parties thereto and acknowledged and agreed by the Company. Pursuant to the RPA Amendment, among other things, (i) the scheduled termination date was extended to January 26, 2029, (ii) a committed $125 million accordion facility was added, permitting Labcorp Receivables at its option to increase the facility limit from $700 million to up to $825 million at any time on or before May 29, 2026, and (iii) the 0.10% SOFR adjustment that was previously added to capital accruing yield at daily 1M SOFR or term SOFR rate was removed.

Labcorp Receivables is a separate legal entity with its own separate creditors who will be entitled to access Labcorp Receivables assets before the assets become available to the Company. Accordingly, Labcorp Receivables assets are not available to pay creditors of the Company or any of its subsidiaries (other than Labcorp Receivables), although collections from the receivables in excess of amounts required to repay the Purchasers and other creditors of Labcorp Receivables may be remitted to the Company.

The foregoing description of the RPA Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the RPA Amendment, a copy of which is filed herewith as Exhibits 10.1 and the terms of which are incorporated herein by reference.


Item 2.03			Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 above is incorporated by reference into this Item 2.03.


Item 9.01			Financial Statements and Exhibits.
Exhibit			Exhibit Name
Exhibit 10.1			Second Amendment to Receivables Purchase Agreement dated as of January 28, 2026
Exhibit 104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABCORP HOLDINGS INC.

Registrant




Date: January 29, 2026	By:	/s/ KATHRYN W. KYLE
		Kathryn W. Kyle
		Executive Vice President, Chief Legal Officer and Corporate Secretary

Source: View Original Filing on SEC EDGAR